A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose) in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis.
Phase of Trial: Phase III
Latest Information Update: 27 Oct 2012
At a glance
- Drugs Certoparin sodium (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms MEMBRANE
- 27 Oct 2012 Planned number of patients changed from 100 to 110 as reported by European Clinical Trials Database record.
- 09 Jul 2012 Actual patient number added as reported by ClinicalTrials.gov.
- 26 May 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2010-019200-23).